Page 70 - Read Online

Page 324 Meyer et al. Cancer Drug Resist 2019;2:313-25 I http://dx.doi.org/10.20517/cdr.2019.11

childhood B-cell acute lymphoblastic leukaemia. Br J Haematol 2013;160:406-9.
15. Hogan LE, Meyer JA, Yang J, Wang J, Wong N, et al. Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia
reveals therapeutic strategies. Blood 2011;118:5218-26.
16. Kraszewska MD, Dawidowska M, Larmonie NSD, Kosmalska M, Sędek Ł, et al. DNA methylation pattern is altered in childhood T-cell
acute lymphoblastic leukemia patients as compared with normal thymic subsets: insights into CpG island methylator phenotype in T-ALL.
Leukemia 2012;26:367-71.
17. Borssén M, Palmqvist L, Karrman K, Abrahamsson J, Behrendtz M, et al. Promoter DNA methylation pattern identifies prognostic
subgroups in childhood T-cell acute lymphoblastic leukemia. PLoS One 2013;8:e65373.
18. Teachey DT, Hunger SP. Predicting relapse risk in childhood acute lymphoblastic leukaemia. Br J Haematol 2013;162:606-20.
19. Borssén M, Haider Z, Landfors M, Norén-Nyström U, Schmiegelow K, et al. DNA methylation adds prognostic value to minimal
residual disease status in pediatric T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer 2016;63:1185-92.
20. Haider Z, Larsson P, Landfors M, Köhn L, Schmiegelow K, et al. An integrated transcriptome analysis in T-cell acute lymphoblastic
leukemia links DNA methylation subgroups to dysregulated TAL1 and ANTP homeobox gene expression. Cancer Med 2019;8:311-24.
21. Audia JE, Campbell RM. Histone Modifications and Cancer. Cold Spring Harb Perspect Biol 2016;8:a019521.
22. Chi P, Allis CD, Wang GG. Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers. Nat Rev
Cancer 2010;10:457-69.
23. Blobel GA. CREB-binding protein and p300: molecular integrators of hematopoietic transcription. Blood 2000;95:745-55.
24. Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia.
Nature 2011;471:235-9.
25. Gao J, Liu WJ. Prognostic value of the response to prednisone for children with acute lymphoblastic leukemia: a meta-analysis. Eur Rev
Med Pharmacol Sci 2018;22:7858-66.
26. Inthal A, Zeitlhofer P, Zeginigg M, Morak M, Grausenburger R, et al. CREBBP HAT domain mutations prevail in relapse cases of high
hyperdiploid childhood acute lymphoblastic leukemia. Leukemia 2012;26:1797-803.
27. Gao C, Zhang RD, Liu SG, Zhao XX, Cui L, et al. Low CREBBP expression is associated with adverse long-term outcomes in
paediatric acute lymphoblastic leukaemia. Eur J Haematol 2017;99:150-9.
28. Moreno DA, Scrideli CA, Cortez MAA, de Paula Queiroz R, Valera ET, et al. Differential expression of HDAC3, HDAC7 and HDAC9
is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. Br J Haematol 2010;150:665-73.
29. Sonnemann J, Gruhn B, Wittig S, Becker S, Beck JF. Increased activity of histone deacetylases in childhood acute lymphoblastic
leukaemia and acute myeloid leukaemia: support for histone deacetylase inhibitors as antileukaemic agents. Br J Haematol
2012;158:664-6 .
30. Gruhn B, Naumann T, Gruner D, Walther M, Wittig S, et al. The expression of histone deacetylase 4 is associated with prednisone poor-
response in childhood acute lymphoblastic leukemia. Leuk Res 2013;37:1200-7.
31. Bachmann PS, Piazza RG, Janes ME, Wong NC, Davies C, et al. Epigenetic silencing of BIM in glucocorticoid poor-responsive
pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood 2010;116:3013-22.
32. Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, et al. MLL targets SET domain methyltransferase activity to Hox gene
promoters. Mol Cell 2002;10:1107-17.
33. Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005;121:167-78.
34. Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, et al. H3K79 methylation profiles define murine and human MLL-AF4
leukemias. Cancer Cell 2008;14:355-68.
35. Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, et al. MLL-rearranged acute lymphoblastic leukemias activate bcl-2
through h3k79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199. Cell Rep 2015;13:2715-27.
36. Mar BG, Bullinger LB, McLean KM, Grauman PV, Harris MH, et al. Mutations in epigenetic regulators including SETD2 are gained
during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun 2014;5:3469.
37. Mar BG, Chu SH, Kahn JD, Krivtsov AV, Koche R, et al. SETD2 alterations impair DNA damage recognition and lead to resistance to
chemotherapy in leukemia. Blood 2017;130:2631-41.
38. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, et al. Phase 1/2 study of the combination of 5-aza-2’-
deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108:3271-9.
39. Schafer E, Irizarry R, Negi S, McIntyre E, Small D, et al. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia:
biology and therapeutic targeting. Blood 2010;115:4798-809.
40. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by
DOT1L. Cancer Cell 2011;20:66-78.
41. Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, et al. Potent inhibition of DOT1L as treatment of MLL-fusion
leukemia. Blood 2013;122:1017-25.
42. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the
treatment of myeloid neoplasms. Cancer Res 2006;66:6361-9.
43. Bhatla T, Wang J, Morrison DJ, Raetz EA, Burke MJ, et al. Epigenetic reprogramming reverses the relapse-specific gene expression
signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. Blood 2012;119:5201-10.
44. Burke MJ, Lamba JK, Pounds S, Cao X, Ghodke-Puranik Y, et al. A therapeutic trial of decitabine and vorinostat in combination with
chemotherapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol 2014;89:889-95.
45. Vilas-Zornoza A, Agirre X, Abizanda G, Moreno C, Segura V, et al. Preclinical activity of LBH589 alone or in combination with